Status:
COMPLETED
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Collaborating Sponsors:
Paragon Biomedical
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis
Eligibility Criteria
Inclusion
- Diagnosis of Psoriasis for 6 mo.
- BSA 10%, PASI 12 or above, PGA 3 or above
Exclusion
- Previous exposure to either etanercept or ABT-874
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
347 Patients enrolled
Trial Details
Trial ID
NCT00691964
Start Date
May 1 2008
End Date
March 1 2009
Last Update
January 21 2013
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 8478
Tucson, Arizona, United States, 85710
2
Site Reference ID/Investigator# 8462
Fresno, California, United States, 93720
3
Site Reference ID/Investigator# 8454
Los Angeles, California, United States, 90045
4
Site Reference ID/Investigator# 8476
Denver, Colorado, United States, 80209